

## **Lincoln Pharma reports 23% rise in standalone net profit at Rs 14.99 Cr in Q1FY21**

21 August 2020 | News

**Becomes a Zero net-debt company paying its outstanding debt to the Financial Institution**



Ahmedabad based Lincoln Pharmaceuticals Ltd., one of the leading healthcare companies has reported a net profit of Rs. 14.99 crore for the Q1FY21 ended June 2020 as against a net profit of Rs. 12.16 crore in the corresponding period last year, growth of 23.2%.

Net revenue for the quarter ended June 2020 reported at Rs. 103.01 crores, higher by 7.11% over previous fiscal's same period net revenue of Rs. 96.17 crore. EBITDA for the quarter ended June 2020 was reported at Rs.22.42 crores as compared to Rs.19.04 crores in the corresponding period last year. EPS was at Rs.7.50 per share for Q1FY21 as compared to Rs.6.08 in the corresponding period last year.

The company has received European Union (EU) GMP certification from Germany FDA for its manufacturing facility located at Khatraj in Gujarat. The certification will allow the company to market its products in all the 27 member countries of EU and also give access to the European Economic Area (EEA) countries.

Exports have increased to 56% of total sales in FY20 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America, and Southeast Asia and has got many product registrations in these countries and is also awarded with a number of global tenders.

The company has recently launched Chewable Vitamin C + Zinc Tablet for Indian market. The tablet is an evidence-based bio-active for natural immunity in a combination of zinc that boosts antiviral activity and protection against COVID 19.